"The difficulty we faced at that time is that pricing and reimbursement issues had never been discussed as part of a trade agreement," said BIO's Joseph Damond. …
Latest Video
New Stories
-
The committee that rarely fronts is called to answer at Senate Estimates
October 19, 2026 - - Latest News -
Cancer physicians now running communication skills workshops on how to discuss private pay
October 19, 2026 - - Latest News -
'If your doctor prescribes it, it should be covered,' pollster recommends as the key message
October 19, 2026 - - Latest News -
Global headwinds and new contenders set the agenda for Australia's 'Biggest Week in Biotech'
October 19, 2026 - - Latest News -
Mixed PBAC outcomes for multi-cancer immunotherapy listings
October 19, 2026 - -
Pharmac funding wins backing across New Zealand's political divide
October 19, 2026 - - Latest News -
Tavneos to be withdrawn from Australia as CSL pulls vasculitis treatment
October 16, 2026 - - Latest News